TYR and melanoma: A similar study using a PD-1:CD28 CSR construct showed that its co-expression is equally beneficial for CD4+ and CD8+ T cells, and can improve the functional avidity of TCRs targeting tyrosinase in xenograft models of human melanoma [219].